Which combination of antipsychotics is known for treating resistant depression?

The combination of Rexulti and Seroquel XR is recognized for its potential in treating resistant depression. Rexulti (brexpiprazole) is an atypical antipsychotic often used as an adjunct treatment for major depressive disorder when initial antidepressants have not achieved the desired response. It works by modulating various neurotransmitter systems, primarily dopamine and serotonin pathways, which can enhance the overall antidepressant effects when paired with mood stabilizers or antidepressants.

Seroquel XR (quetiapine) is also an atypical antipsychotic that is effective in treating mood disorders, including bipolar depression and major depressive disorder. Its sedative properties and ability to stabilize mood can complement the action of Rexulti, thus providing a more robust treatment option for those who have not responded adequately to first-line therapies.

Together, these two medications can address the complex neurochemical interactions involved in depression, offering a synergistic effect that can help manage difficult cases. This combination is particularly relevant for patients who demonstrate resistance to standard antidepressant protocols, making it a valuable treatment strategy in clinical practice for managing resistant depression.